References
- Wong ES. Surgical site infection. In Mayhall DG, ed. Hospital epidemiology and infection control. 2nd edn. Philadelphia: Lippincott, Williams & Wilkins, 1999: 189–210.
- Hollenbeak CS, Murphy D, Dunagan WC, Fraser VJ. Nonrandom selection and the attributable cost of surgical-site infections. Infect Control Hosp Epidemiol. 2002; 23: 177–182.
- Perencevich EN, Sands KE, Cosgrove SE, Guadagnoli E, Meara E, Platt R. Health and economic impact of surgical site infections diagnosed after hospital discharge. Emerg Infect Dis. 2003; 9: 196–203.
- Salma TG. Current thoughts and controversies of antibi-otic prophylaxis. Current Opinion Infect Dis 1992; 5: 787–798.
- Kriaras I, Michalopoulos A, Michalis A, et al: Prophylaxis in cardiac surgery. J Cardiovasc Surg (Torino) 1997; 38: 605–610.
- Saginur R, Croteau D, Bergeron MG. Comparative effi-cacy of teicoplanin and cefazolin for cardiac operation prophy-laxis in 3027 patients. The ESPRIT Group. J Thorac Cardiovasc Surg 2000; 120: 1120–1130.
- Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection. Infect Control Hosp Epidemiol 1999; 20: 250–278.
- Naber KG, Bergman B, Bishop MC, et al. EAU guide-lines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 2001; 40: 576–588.
- Matsukawa M, Kunishima Y, Takahashi S, Takeyama K, Tsukamoto T. Staphylococcus aureus bacteriuria and surgical site infections by methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2001; 17: 327–329.
- Kanamaru S, Terai A, Ishitoya S, et al. Assessment of a protocol for prophylactic antibiotics to prevent perioperative infection in urologic surgery: a preliminary study. Int J Urol 2004; 11: 355–363.
- Takeyama K, Shimizu T, Mutoh M, et al. Prophylactic antimicrobial agents in urologic laparoscopic surgery: 1-day versus 3-day treatments. J Infect Chemother 2004; 10: 168–171.
- Gasser TC, Wisard M, Frei R. Oral fleroxacin prophy-laxis in transurethral surgery. J Urol 1996; 156: 146–148.
- Hall JC, Christiansen KJ, England P et al. Antibiotic prophylaxis for patients undergoing transurethral resection of the prostate. Urology 1996; 47: 852–856.
- Vuorisalo S, Haukipuro K, Pokela R, Syrjala H. Risk features for surgical-site infections in coronary artery bypass surgery. Infect Control Hosp Epidemiol 1998; 19: 240–247.
- Bratzler DW, Houck PM, for Surgical Infection Prevention Guidelines Writers Workgroup. Antimicrobial pro-phylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38: 1706–1715.
- Morikane K, Konishi T, Nishioka M, Harihara Y, Kobayashi H. The present status of surgical site infections in Japan: from the report of the Japanese Nosocomial Infections Surveillance (JNIS) system. Jpn J Surg Infect 2003; 15: 103–107.
- ASHP therapeutic guidelines on antimicrobial prophy-laxis in surgery. American Society of Health-System Pharmacists. Am J Health Syst Pharm 1999; 56: 1839–1888.
- Eachempati SR, Hydo L, Buie PS. Gender-based dif-ferences in outcome in patients with sepsis. Arch Surg 1999; 134: 1342–1347.
- Richards C, Edwards J, Culver D et al. Does using a laparoscopic approach to cholecystectomy decrease the risk of surgical site infection? Ann Surg 2003; 237: 358–362.
- Kingston RD, Walsh S, Robinson C, Jeacock J, Keeling F. Significant risk factors in elective colorectal surgery. Ann R Coll Surg Engl 1995; 77: 369–371.